Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Meningococcal Disease Clear all

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 21 Years
Enrollment: 55,397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California

Conditions: Meningococcal Vaccine
Interventions: Awareness, Education, Empowerment, Accessibility; Other
Lead sponsor: University of Florida; Other
Eligibility: 16 Years to 99 Years
Enrollment: 1,326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Gainesville, Florida

Conditions: Meningococcal Infections, Meningitis
Interventions: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: East Stroudsburg, Pennsylvania

Conditions: Meningococcal Disease, Pregnancy, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, North Carolina

Conditions: Meningococcal Infections, Meningococcal Meningitis
Interventions: MenACWY CRM, Meningococcal ACWY Conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 3,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more

Conditions: Infections, Meningococcal
Interventions: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,558 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more

Conditions: Meningitis, Meningococcal Infection, Neisseria Meningitidis
Interventions: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boca Raton, Florida + 12 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 19 Months
Enrollment: 950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: MenACWY-CRM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Lake Mary, Florida + 15 more

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Bardstown, Kentucky • Woburn, Massachusetts • Niles, Michigan + 1 more

Conditions: Meningitis, Meningococcemia, Neisseria Meningitidis
Interventions: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 5 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 8
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 249 Days to 305 Days
Enrollment: 1,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 39
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK134612; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Months to 9 Months
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Guillain-Barre Syndrome
Interventions: Not listed
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 11 Years to 21 Years
Enrollment: 6,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 6
States / cities: Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more

Conditions: Infections, Meningococcal
Interventions: Bexsero, Saline Placebo, Havrix, MenABCWY; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 1,063 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,797 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 67
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 56 Years and older
Enrollment: 907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 35
States / cities: Chandler, Arizona • Anaheim, California • San Diego, California + 28 more

Conditions: Invasive Meningococcal Disease
Interventions: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Prevention of Meningococcal Disease
Interventions: MenACWY-CRM Vaccine, MenACWY-PS Vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 12 Months to 10 Years
Enrollment: 910 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: rLP2086; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Meningococcal Meningitis
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 37 Months to 63 Months
Enrollment: 433 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • Downey, California • Oakland, California + 15 more

Conditions: HIV Infections, Meningitis
Interventions: Quadrivalent meningococcal conjugate vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 35
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 25 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more

Search by objective public record fields.

Safety of MenACWY-CRM Vaccination in Adolescents

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Dose Comparison Study of Menactra® in US Children

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Safety Surveillance of MenACWY-CRM Vaccine in Children

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Safety Study of GBS Following Menactra Meningococcal Vaccination

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine